Trump’s Tariff Plans Take Shape

Summary

Podcast Summary: WSJ What’s News – "Trump’s Tariff Plans Take Shape" Release Date: November 26, 2024

Hosted by The Wall Street Journal, WSJ What’s News provides listeners with the most significant news of the day, spanning business, finance, global affairs, and political developments that influence markets. In the episode titled "Trump’s Tariff Plans Take Shape," released on November 26, 2024, the focus centers on former President Donald Trump’s newly unveiled tariff strategies and their multifaceted implications.

---

1. Overview of Trump's Tariff Plans

Donald Trump's Announcement:

• Tariffs on Mexico and Canada: Trump has pledged to impose a 25% tariff on all U.S. exports to Mexico and Canada starting on his first day in office. This move signals his intent to renegotiate the terms of the USMCA (United States-Mexico-Canada Agreement), a free trade pact established during his first term.

• Tariffs on China: Additionally, Trump announced an additional 10% tariff on Chinese products entering the U.S., supplementing the tariffs already in place. However, the timeline for these tariffs remains unspecified.

Rationale Behind the Tariffs:

• Illicit Drug Trade: Trump linked his tariff threats to the failure of Mexico, Canada, and China in curbing the flow of illicit drugs, particularly fentanyl. He criticized these nations for not doing enough to combat the drug crisis in the U.S.

• Illegal Immigration: For Canada and Mexico, illegal immigration serves as another justification for the proposed tariffs.

Notable Quotes:

• Luke Vargas introduces the topic by stating, “President elect Donald Trump is promising to charge Mexico and Canada a 25% tariff on all of their U.S. exports beginning on his first day in office, a clear signal he wants to rewrite the terms of the USMCA agreement” [00:51].

---

2. International Responses and Economic Implications

China's Reaction:

• A spokesperson from China’s embassy in Washington responded, “No one will win a trade war or a tariff war,” indicating a defensive stance against Trump’s proposals.

Canada and Mexico's Stance:

• Canada: The Canadian government expressed intentions to continue discussions on trade and border security with the incoming Trump administration.

• Mexico: Mexican officials are in a precarious position as Chinese electric vehicle maker BYD finalizes plans to establish a factory in Mexico. Mexican states have reduced incentives for BYD to avoid perceptions of Mexico becoming a conduit for Chinese companies into the U.S. market.

Market Reactions:

• Currency Markets: In response to Trump’s tariffs, the Mexican peso and Canadian dollar weakened, while the Chinese yuan experienced a modest decline against the U.S. dollar.

• Stock Markets:

  • Shares of Jeep manufacturer Stellantis fell over 5% in European trading.
  • German automakers Volkswagen, BMW, and Mercedes-Benz also saw declines in their stock prices [03:12].

Notable Quotes:

• Ben Dummett remarks on currency fluctuations, stating, “Separately, we've seen other so called haven currencies including the Japanese yen strengthening, though there are some analysts who know. We just don't know yet what Trump's going to do or what he's going to say between now and inauguration that actually could upend that so called safety” [03:12].

---

3. Impact on the Automotive Sector

California’s Response to Potential Federal EV Tax Credit Cuts:

• Governor Gavin Newsom’s Initiative: In anticipation of Trump potentially cutting the federal $7,500 tax credit for electric vehicles (EVs), California plans to offer rebates funded by refineries, food manufacturing plants, and other facilities contributing to state greenhouse gas emissions.

• Eligibility Concerns: The Democrat office clarified that vehicles manufactured by Tesla and possibly other companies won't qualify for these rebates to foster market competition. Tesla declined to comment on this issue [03:44].

Market Impact:

• The automotive sector is directly affected, with significant drops in shares of major automakers as uncertainty looms over trade policies and federal incentives for EVs.

Notable Quotes:

• Luke Vargas highlights the automotive sector's volatility: “Shares in Jeep maker Stellantis fell more than 5% in morning trading in Europe, while Germany's Volkswagen, BMW and Mercedes Benz also saw their shares slip” [03:44].

---

4. Biden Administration's Healthcare Proposal

Expansion of Medicare and Medicaid Coverage:

• The Biden administration has unveiled a plan to allow Medicare and Medicaid to cover popular weight loss drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, even for obese Americans without other conditions like diabetes.

• Coverage Details:

  • Estimated to benefit 3.4 million Medicare-insured Americans and an additional 4 million Medicaid beneficiaries.

• Financial Implications:

  • The plan would require tens of billions of dollars in additional funding, posing a challenge for the incoming Trump administration, which has pledged to reduce federal spending.

Notable Quotes:

• Vargas notes the administration's proposal: “The White House says the proposed change would extend coverage of drugs such as Novo Nordisk's WeGovy and Eli Lilly's Zepbound to an estimated 3.4 million Americans insured by Medicare and an additional 4 million by Medicaid” [03:44].

---

5. Legal Issues in the Financial Sector

Fraud Charges Against Ken Leach:

• Allegations: Ken Leach, a long-time bond investor and former Chief Investment Officer at Franklin Templeton’s Western Asset Management, faces fraud charges for allegedly allocating over $600 million in gains to preferred clients while transferring losses to others.

• SEC Involvement: The Securities and Exchange Commission (SEC) is also pursuing charges, asserting that Leach engaged in a “cherry-picking” scheme by selectively allocating profitable trades to certain accounts.

• Franklin Templeton’s Response: The company is cooperating fully with the investigations, amid client withdrawals triggered by the ongoing probe [06:49].

Notable Quotes:

• The SEC’s description: “The so called cherry picking scheme involved placing trades and then waiting to see how they performed during the day before allocating them to Klein account” [03:44].

---

6. In-Depth Analysis: Brian Spiegel on Trump's Tariff Strategy and China's Response

Interview with Brian Spiegel:

• Contextualizing the Drug Crisis: Brian Spiegel, a senior WSJ correspondent in Beijing, discusses the severity of the U.S. drug overdose crisis, highlighting that over 107,000 deaths in the previous year were attributed to fentanyl and similar synthetic opioids [07:27].

• Previous Efforts and Challenges:

  • During Trump’s first term, China was persuaded to regulate fentanyl more strictly, but enforcement gaps remain as Chinese companies continue supplying precursor chemicals used in fentanyl production.
  • The Biden administration aimed to build trust and cooperation with China on counters narcotics, but results have been limited [08:10].

Trump’s Maximal Pressure Campaign:

• Strategy Shift: Unlike the Biden administration’s cooperative approach, Trump is adopting a “maximal pressure” strategy, tying tariffs directly to China’s role in the fentanyl trade.

• Potential Outcomes:

  • China’s Response: Spiegel suggests that China may view Trump’s tactics as coercive, leading to a breakdown in existing law enforcement cooperation channels.
  • Continuation of Tensions: If China perceives that tariffs will be imposed regardless of cooperation on drug trafficking, it may reduce collaborative efforts, hindering progress on the fentanyl crisis [09:40].

Domestic Political Considerations:

• Risk of Diplomatic Strain: Trump’s aggressive stance might lead China to disengage from dialogue, potentially freezing cooperation on narcotics control and affecting broader U.S.-China relations [10:23].

Notable Quotes:

• Spiegel on the fentanyl crisis: “Last year, it's estimated that more than 107,000 people died in the United States of drug overdoses, and the majority of them were deaths from fentanyl and other similar drugs known as synthetic opioids” [07:27].

• On Trump’s strategy: “I think that this is going to be a maximal pressure campaign against China. It's an open question whether this is going to work” [09:40].

• Spiegel on potential fallout: “China does not appreciate that whatsoever. Yet nevertheless, they say from a humanitarian perspective, we are willing to work with the United States if we're treated with respect and the conditions are right” [10:23].

---

Conclusion and Forward Look

The episode delves into the complexities of Trump's proposed tariff measures and their broader implications on international trade, diplomatic relations, and domestic policies. The strategic linkage of tariffs to the fentanyl crisis introduces new dimensions to U.S.-China relations, potentially reshaping cooperation dynamics. Additionally, domestic policies such as California’s EV rebates and the Biden administration’s healthcare proposals highlight the ongoing intersection of federal and state initiatives amid changing political landscapes. Legal challenges within the financial sector, exemplified by Ken Leach’s case, underscore the persistent regulatory scrutiny within significant economic sectors.

Listeners are left to anticipate how these multi-layered developments will unfold as Trump assumes office, with particular attention to the sustainability of China-U.S. cooperation on critical issues like the drug epidemic and the potential ripple effects across global markets.

---

Produced by Daniel Bach and Kate Bullivant, with supervising producer Christina Rocca.

Transcript

[Robert Half]

Robert Half research indicates nine out of 10 hiring managers are having difficulty hiring. Robert Half is here to help our recruiting professionals utilize our proprietary AI to connect businesses with highly skilled talent. At Robert Half, we know talent. Visit roberthaff.com today.

[Luke Vargas]

Donald Trump offers new details on his promised tariffs targeting Mexico, Canada and China. Plus, we'll go inside Trump's plan to put maximum pressure on Beijing to stem the illicit drug trade.

[Brian Spiegel]

If you are the Chinese leadership in Beijing and you do agree to effectively do what the Trump administration is asking you to do, to what extent are you going to look weak in the eyes of your own people? Right? Many of the experts that we talk to about this, that's simply not how you get the Chinese to change their behavior.

[Luke Vargas]

And the White House proposes a major expansion of Medicare and Medicaid's coverage of anti obesity drugs. It's Tuesday, November 26th. I'm Luke Vargas for the Wall Street Journal and here is the AM edition of what's news, the top headlines and business stories moving your world. Today, President elect Donald Trump is promising to charge Mexico and Canada a 25% tariff on all of their U.S. exports beginning on his first day in office, a clear signal he wants to rewrite the terms of the USMCA agreement, the free trade pact that negotiated in his first term. Posting on Truth Social, Trump added that all Chinese products bound for the US would face an additional 10% tariff on top of those the US has already imposed, though he didn't specify when. It wasn't immediately clear what legal authority Trump will invoke to justify the tariffs, though he faulted America's neighbors and China for not doing enough to stop the flow of drugs, especially fentanyl. He also cited illegal immigration as a rationale for the measures targeting Canada and Mexico. A spokesman for China's embassy in Washington said that no one will win a trade war or a tariff war. Canada's government said it would keep discussing trade and border security issues with the incoming administration, while representatives at Mexico's embassy didn't respond to a request for comment. Well, Trump's tariff threat is putting Mexican officials in a bind as Chinese electric vehicle maker BYD finalizes plans for a factory in the country. While the BYD plant would normally represent a welcome foreign investment, officials fear the plant could suggest that Mexico wants to be a back door for Chinese companies to sell to Americans, according to people familiar with the matter. Several Mexican states have dialed back incentives they're offering to BYD to attract the plant, and we report the federal government isn't happy with BYD's timing potentially jeopardizing necessary consent for the investment. And currency markets are moving today in response to Trump's tariff pledges, with the Mexican peso and Canadian doll dollar weakening and the Chinese yuan falling modestly against the dollar. Our Ben Dummett has more.

[Ben Dummett]

Separately, we've seen other so called haven currencies including the Japanese yen strengthening, though there are some analysts who know. We just don't know yet what Trump's going to do or what he's going to say between now and inauguration that actually could upend that so called safety. That's especially true in Europe, where analysts from ing, for example, have noted that policymakers are particularly fearful that Trump attention to the Continent's auto sector, a possibility that's already pressuring the euro lower today.

[Luke Vargas]

Shares in Jeep maker Stellantis fell more than 5% in morning trading in Europe, while Germany's Volkswagen, BMW and Mercedes Benz also saw their shares slip. Well, speaking of the auto sector, California Governor Gavin Newsom says the state will intervene to offer rebates for EVs if Donald Trump cuts a $7,500 federal tax credit for the cars, setting up what could be a long batt Trump administration Newsom said the EV rebates would be funded by refineries, food manufacturing plants and other facilities that pay the state to emit greenhouse gases. However, the Democrats office said that cars made by Elon Musk's, Tesla and potentially other manufacturers may not be eligible for the rebate program to encourage market competition. Tesla didn't return a request for comment. The Biden administration is proposing a plan for Medicare and Medicaid to pay for popular weight loss drugs for more obese Americans even if they don't have other diseases like diabetes. The White House says the proposed change would extend coverage of drugs such as Novo Nordisk's WeGovy and Eli Lilly's Zepbound to an estimated 3.4 million Americans insured by Medicare and an additional 4 million by Medicaid. The plan to cover the drugs, which list for more than $1,000 a month, would add tens of billions of dollars in outlays to the programs and would need finalized by the Trump administration, which has pledged to cut federal spending. And federal prosecutors are charging long time bond investor Ken Leach with fraud, alleging he assigned more than $600 million in gains to preferred clients while offloading losses on others. The securities and Exchange Commission is also charging Leach in a separate action saying the so called cherry picking scheme involved placing trades and then waiting to see how they performed during the day before allocating them to Klein account. In a statement, Leach's lawyer called the allegations unfounded. Leach was, until very recently chief investment officer at Franklin Templeton subsidiary Western Asset Management. The firm has been reeling from client outflows since disclosing that Leach was under investigation earlier this year. A company spokeswoman said Franklin is fully cooperating with the probes. Coming up with Donald Trump tying the threat of tariffs to the flow of illicit drugs, we'll look at how Beijing might respond to a more combative position over its role in the fentanyl crisis. We've got that story after the break.

[Robert Half]

Robert Half research indicates nine out of 10 hiring managers are having difficulty hiring. Robert Half is here to help our recruiting professionals utilize our proprietary AI to connect businesses with highly skilled talent. At Robert Half, we know talent. Visit roberthaff.com today.

[Luke Vargas]

When Donald Trump vowed last night to impose tariffs on China and Mexico, he directly tied them to the issue of the international narcotics trade, particularly in fentanyl. It's something he repeatedly brought up in the closing days of his campaign, vowing to tariff the hell out of China unless it helps to stop the flow of illicit drugs into the U.S. so how is Beijing likely to respond to Trump's hardball tactics? Brian Spiegel is a senior Wall Street Journal correspondent based in Beijing. Brian, the stakes surrounding the drug crisis, including around fentanyl, are about as high as they come, aren't they?

[Brian Spiegel]

Yeah, that's right. Last year, it's estimated that more than 107,000 people died in the United States of drug overdoses, and the majority of them were deaths from fentanyl and other similar drugs known as synthetic opioids. It's an absolutely tremendous number. And for multiple administrations now, it's been a tricky issue to solve. So back in Trump's first term, China was selling fentanyl itself to the United States illicitly. And Trump got Chinese leader Xi Jinping to classify or to regulate much more strictly fentanyl itself as a class of drugs. But the problem is that Chinese companies continue to sell the chemicals, the building blocks used to make fentanyl. And that's really become the central point of focus today.

[Luke Vargas]

Right. Which the Biden administration has also tried to tackle.

[Brian Spiegel]

Yeah, they basically said, okay, there's a whole host of things that China and the United States disagree on. Counternarcotics should not be one of those things. So why can't we use this as kind of a testing ground to see if we can build trust in the relationship, but also push China, you want to be seen as a great, responsible power in the world. Work with us on this. Do it the right way.

[Luke Vargas]

All right, so kind of using the carrot as opposed to the stick that we're going to talk about from Trump a little bit later. Just give us a sense of what the that has looked like the last few years.

[Brian Spiegel]

Two things, I would say. One is they've gotten China to regulate more strictly some of these specific chemicals that are used to make fentanyl. The Biden administration said it took China way too long to do this, but they are happy nevertheless. The second part is law enforcement cooperation. For a while now, the United States has been sharing intelligence with China, saying, we know who are the bad guys selling these chemicals to the Mexican cartels, and the Mexican cartels are making the fence and sending to the United States. You should go after and arrest those people. Just recently, we've seen China beginning to make some moves, so that kind of cooperation can fall apart very easily. But it's been hard won by the Biden administration.

[Luke Vargas]

And yet, clearly, Brian Trump thinks that approach is coming up short. And it's not just him. Trump's incoming National Security advisor, Mike Waltz, claimed last month, in his words, that China is working with the cartels to infiltrate the U.S. what are we likely to see if Trump follows through on what he's been saying on the campaign trail?

[Brian Spiegel]

Yeah, I think that this is going to be a maximal pressure campaign against China. It's an open question whether this is going to work. Back in 2018, when Trump did have some success in convincing China on fentanyl, China was very desperate to do a deal. Now the question is, as Trump comes back into power, is China basically going to conclude Trump's going to put tariffs on us no matter what? We did a deal with fentanyl with Trump back in 2018, and yet he's still threatening tariffs against us. Why are we going to play ball with you again?

[Luke Vargas]

And, Brian, from your reporting, it sounds like there are also some potentially sensitive domestic political considerations around all of this as well. Right. Which begs the question, if Trump's hardball tactics aren't successful, where might that leave us?

[Brian Spiegel]

So if Trump comes in from day one and is seen domestically as trying to bully or pressure the Chinese on this issue, there's a real risk that China is going to clam up and they're not going to want to continue kind of the channels that they had with the Biden administration. Now, that doesn't mean they're going to reverse regulation that they've already now implemented. However, we could see them freeze the sorts of law enforcement channels of communication that we've seen if they don't like the way that Trump is trying to approach this conversation. More fundamentally, the way China views this situation is they think US Politicians are trying to use China as a scapegoat for their own failures of dealing with America's opioid addiction crisis. China does not appreciate that whatsoever. Yet nevertheless, they say from a humanitarian perspective, we are willing to work with the United States if we're treated with respect and the conditions are right.

[Luke Vargas]

I've been speaking to Wall Street Journal senior correspondent Brian Spiegel in Beijing. Brian, thanks so much for the update.

[Brian Spiegel]

Thank you.

[Luke Vargas]

And that's it for what's news for Tuesday morning. Today's show was produced by Daniel Bach and Kate Bullivant with supervising producer Christina Rocca. And I'm Luke Vargas for the Wall Street Journal. We will be back tonight with a new show and until then, thanks for listening.